What does this research mean for the field?

Avelumab plus axitinib has a high probability of providing some overall survival benefit compared to sunitinib in advanced renal cell carcinoma, but a low probability of exceeding the minimal clinically important difference, except potentially in poor-risk patients. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This study aims to reinterpret the treatment effects of avelumab plus axitinib in advanced renal cell carcinoma using Bayesian methods.

June 1, 2026Cancer MedicineOpen Access

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

WFWataru Fukuokaya KMKeiichiro Mori TYTakafumi Yanagisawa

Discussion

Member takes

Overview

Bayesian trial analysis shows treatment effect variations in advanced renal cell carcinoma based on risk groups, suggesting nuanced interpretations.

Key Points

This study aims to reinterpret the treatment effects of avelumab plus axitinib in advanced renal cell carcinoma using Bayesian methods.
Reanalyzed individual participant data from the JAVELIN Renal 101 trial using Bayesian frameworks.
Estimated probabilities of overall survival benefits using Bayesian Cox models.
Performed subgroup analyses based on risk groups and PD-L1 status.
The probability of overall survival benefit (HR < 1.0) was high (93.0% to 95.5%).
However, the probability of exceeding the minimal clinically important difference (HR < 0.75) was low (1.0% to 3.8%).
Subgroup analyses revealed probabilities of HR < MCID varied significantly by risk group, from 63.4% for poor-risk to 0.9% for intermediate-risk.

Cite This Study

Fukuokaya et al. (2026) studied this question.

synapsesocial.com/papers/6a1d224302fbce913063816d https://doi.org/10.1002/cam4.71999

View Full Paper

Ask AI

Bookmark

June 1, 2026Cancer MedicineOpen Access

Bayesian Evaluation of Treatment Effect of Avelumab Plus Axitinib for Advanced Renal Cell Carcinoma

View Full Paper

Ask AI

Bookmark

Authors

WFWataru Fukuokaya KMKeiichiro Mori TYTakafumi Yanagisawa

Discussion

Member takes

Overview

Bayesian trial analysis shows treatment effect variations in advanced renal cell carcinoma based on risk groups, suggesting nuanced interpretations.

Key Points

This study aims to reinterpret the treatment effects of avelumab plus axitinib in advanced renal cell carcinoma using Bayesian methods.
Reanalyzed individual participant data from the JAVELIN Renal 101 trial using Bayesian frameworks.
Estimated probabilities of overall survival benefits using Bayesian Cox models.
Performed subgroup analyses based on risk groups and PD-L1 status.
The probability of overall survival benefit (HR < 1.0) was high (93.0% to 95.5%).
However, the probability of exceeding the minimal clinically important difference (HR < 0.75) was low (1.0% to 3.8%).
Subgroup analyses revealed probabilities of HR < MCID varied significantly by risk group, from 63.4% for poor-risk to 0.9% for intermediate-risk.

Cite This Study

Fukuokaya et al. (2026) studied this question.

synapsesocial.com/papers/6a1d224302fbce913063816d https://doi.org/10.1002/cam4.71999

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark